Company

TenSixteen Bio, Inc.

TenSixteen Bio develops diagnostics and therapies based on clonal hematopoiesis research.

About

Founded in 2020, TenSixteen Bio uses multi-omics data and diagnostic assays to study clonal hematopoiesis and develop targeted therapies. Based in San Francisco, it raised USD 30 million in Series A funding in January 2022, co-led by Foresite Capital and GV. Mark Chao and Pradeep Natarajan co-founded the company.

1Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in